Could a common antiviral protect babies from CMV in the womb?
NCT ID NCT01651585
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether giving the antiviral drug valacyclovir to pregnant women with a CMV-infected fetus could reduce the chance of the baby being born with serious symptoms. 41 pregnant women took high doses of valacyclovir daily for up to 23 weeks. The goal was to see if the drug could lower the virus level in the baby and improve outcomes at birth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
valacyclovir
What this could lead to
If successful, this could point toward a way to reduce the severity of congenital CMV infection in newborns.
What could go wrong
This was a small, non-randomized trial with 41 participants, so results may not apply broadly. The drug may not prevent all complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL CYTOMEGALOVIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Necker Enfants Malades
Paris, 75015, France